These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 11032019)

  • 1. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation.
    Llovera M; Pichard C; Bernichtein S; Jeay S; Touraine P; Kelly PA; Goffin V
    Oncogene; 2000 Sep; 19(41):4695-705. PubMed ID: 11032019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells.
    Cataldo L; Chen NY; Yuan Q; Li W; Ramamoorthy P; Wagner TE; Sticca RP; Chen WY
    Int J Oncol; 2000 Dec; 17(6):1179-85. PubMed ID: 11078803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A.
    Langenheim JF; Chen WY
    Breast Cancer Res Treat; 2005 Apr; 90(3):281-93. PubMed ID: 15830142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
    Beck MT; Chen NY; Franek KJ; Chen WY
    Cancer Res; 2003 Jul; 63(13):3598-604. PubMed ID: 12839947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel design of targeted endocrine and cytokine therapy for breast cancer.
    Zhang G; Li W; Holle L; Chen N; Chen WY
    Clin Cancer Res; 2002 Apr; 8(4):1196-205. PubMed ID: 11948133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis.
    Chen WY; Ramamoorthy P; Chen N; Sticca R; Wagner TE
    Clin Cancer Res; 1999 Nov; 5(11):3583-93. PubMed ID: 10589775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S179D-human PRL, a pseudophosphorylated human PRL analog, is an agonist and not an antagonist.
    Bernichtein S; Kinet S; Jeay S; Llovera M; Madern D; Martial JA; Kelly PA; Goffin V
    Endocrinology; 2001 Sep; 142(9):3950-63. PubMed ID: 11517174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolactin activates Stat1 but does not antagonize Stat1 activation and growth inhibition by type I interferons in human breast cancer cells.
    Schaber JD; Fang H; Xu J; Grimley PM; Rui H
    Cancer Res; 1998 May; 58(9):1914-9. PubMed ID: 9581833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R.
    Beck MT; Peirce SK; Chen WY
    Oncogene; 2002 Aug; 21(33):5047-55. PubMed ID: 12140755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice.
    Peirce SK; Chen WY
    Oncogene; 2004 Feb; 23(6):1248-55. PubMed ID: 14647416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells.
    Gutzman JH; Miller KK; Schuler LA
    J Steroid Biochem Mol Biol; 2004 Jan; 88(1):69-77. PubMed ID: 15026085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of functional prolactin receptors in nonpregnant human endometrium: janus kinase-2, signal transducer and activator of transcription-1 (STAT1), and STAT5 proteins are phosphorylated after stimulation with prolactin.
    Jabbour HN; Critchley HO; Boddy SC
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2545-53. PubMed ID: 9661641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolactin receptor antagonism in mouse anterior pituitary: effects on cell turnover and prolactin receptor expression.
    Ferraris J; Boutillon F; Bernadet M; Seilicovich A; Goffin V; Pisera D
    Am J Physiol Endocrinol Metab; 2012 Feb; 302(3):E356-64. PubMed ID: 22094470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
    Scotti ML; Langenheim JF; Tomblyn S; Springs AE; Chen WY
    Breast Cancer Res Treat; 2008 Sep; 111(2):241-50. PubMed ID: 17955362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade.
    Li H; Ahonen TJ; Alanen K; Xie J; LeBaron MJ; Pretlow TG; Ealley EL; Zhang Y; Nurmi M; Singh B; Martikainen PM; Nevalainen MT
    Cancer Res; 2004 Jul; 64(14):4774-82. PubMed ID: 15256446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autocrine stimulation of human mammary carcinoma cell proliferation by human growth hormone.
    Kaulsay KK; Mertani HC; Törnell J; Morel G; Lee KO; Lobie PE
    Exp Cell Res; 1999 Jul; 250(1):35-50. PubMed ID: 10388519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells.
    Nouhi Z; Chughtai N; Hartley S; Cocolakis E; Lebrun JJ; Ali S
    Cancer Res; 2006 Feb; 66(3):1824-32. PubMed ID: 16452244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGF stimulates Pit-1 independent transcription of the human prolactin pituitary promoter in human breast cancer SK-BR-3 cells through its proximal AP-1 response element.
    Manfroid I; Van de Weerdt C; Baudhuin A; Martial JA; Muller M
    Mol Cell Endocrinol; 2005 Jan; 229(1-2):127-39. PubMed ID: 15607537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving the pharmacokinetics/pharmacodynamics of prolactin, GH, and their antagonists by fusion to a synthetic albumin-binding peptide.
    Langenheim JF; Chen WY
    J Endocrinol; 2009 Dec; 203(3):375-87. PubMed ID: 19770179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different biological effects of unmodified prolactin and a molecular mimic of phosphorylated prolactin involve different signaling pathways.
    Wu W; Coss D; Lorenson MY; Kuo CB; Xu X; Walker AM
    Biochemistry; 2003 Jun; 42(24):7561-70. PubMed ID: 12809512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.